


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Milne C-P, Davis J. The Pediatric studies initiative: after 15 years have we reached the limits of the law? Clinical Therapeutics. 2014;36(2):156-162. [RS 3407]
http://dx.doi.org/10.1016/j.clinthera.2013.11.007


http://dx.doi.org/10.4155/cli.13.134

DiMasi JA, Kim J, Getz KA. The impact of collaborative and risk-sharing innovation approaches on clinical and regulatory cycle times. Therapeutic Innovation & Regulatory Science. 2014; Published online before print February 5, 2014. [RS 3404]
http://dx.doi.org/10.1177/2168479014521419

Kaitin KI, editor. New breakthrough therapy designation program aims to cut clinical trial time. Tufts Center for the Study of Drug Development Impact Report. 2014 Jan/Feb;16(1)** [RS 3403]


http://dx.doi.org/10.3402/jmahp.v2.23513


http://dx.doi.org/10.1371/journal.pone.0084088

http://dx.doi.org/10.1038/clpt.2013.177

**This publication is for sale at our website http://csdd.tufts.edu/reports**
http://cognoscenti.wbur.org/2013/12/18/series-prescription-drug-pipeline-sidney-wolfe-kenneth-kaitin


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=828039


http://dx.doi.org/10.1038/clpt.2013.155

http://dx.doi.org/10.1586/17512433.2013.841539

Getz KA. Leveraging pharmacists as a channel to raise clinical research literacy among patient communities. Applied Clinical Trials. 2013;22(10):30-33. [RS 3337]
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Articles/Leveraging-Pharmacists-as-a-Channel-to-Raise-Clinical-Literacy-among-Patient-Communities/ArticleStandard/Article/detail/825673


**This publication is for sale at our website http://csdd.tufts.edu/reports

http://www.scripintelligence.com/home/Flexible-global-more-adaptive-clinical-trials-2.0-346528


http://dx.doi.org/10.1038/clpt.2013.129


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Articles/Lifting-Up-a-Fragmented-Study-Conduct-Landscape/ArticleStandard/Article/detail/820680


http://dx.doi.org/10.1517/21678707.2013.819289

http://dx.doi.org/10.1038/clpt.2013.117

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Milne CP, Malins A. Pharmaceutical economics and market access for pediatric medicines. In: Mulberg AE, Murphy D, Dunne D & Mathis LL, eds. Pediatric Drug Development. 2nd ed. Singapore: John Wiley & Sons, Inc.; 2013:37-56. [E-book published in May; Print will be available in August] [RS 3326]


http://dx.doi.org/10.1177/2168479013494386

Milne CP. On the partnering path from the US to Asia: how far, how fast for university-industry collaborations? Pharma Focus Asia. 2013; (18): 40-45. [RS 3323]
http://www.pharmafocusasia.com/strategy/partnering-path-us-asia.htm


http://dx.doi.org/10.1016/j.clinthera.2013.04.004

http://www.panstanford.com/books/9789814316996.html


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Getz KA. Building clinical trial awareness for patients: why not try the pharmacist? *Pharmaceutical Executive*. Published March 1, 2013 [web document] [RS 3315]

Cohen JP. Think twice about how we let overseas use of Plan B guide us [letter to the editor]. *The Boston Globe*. April 21, 2013: K8. [RS 3314]


Cohen JP, Malins A, Shahpurwala Z. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs. *Health Affairs*. 2013;32:762-770 [RS 3312]
[http://content.healthaffairs.org/content/32/4/762.abstract](http://content.healthaffairs.org/content/32/4/762.abstract)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dij.sagepub.com/content/47/3/336


Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin, KI. Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics.* 2013. [Published Ahead-of-Print; Last Updated: April 9, 2013] [RS 3307]
http://dx.doi.org/10.1097/MJT.0b013e31826fc4aa


Kaitin KI, editor. 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. *Tufts Center for the Study of Drug Development Impact Report.* 2013 Jan/Feb;15(1)** [RS 3302]

http://dij.sagepub.com/content/47/1/101.full.pdf


**This publication is for sale at our website** http://csdd.tufts.edu/reports
Getz KA. Op/ed: A way for biopharma to disclose more trial data [editorial].
Medical Marketing and Media. 2012 Dec 26. [web document] [RS 3240]

http://www.annallergy.org/article/S1081-1206(12)00939-8/fulltext

http://dx.doi.org/10.1634/theoncologist.2012-0235


http://link.springer.com/article/10.1007%2Fs12031-012-9803-8


Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. American Journal of Therapeutics. 2012. [Published Ahead-of-Print; Last Updated: January 24, 2013] [RS 3232]

**This publication is for sale at our website  http://csdd.tufts.edu/reports
http://www.topra.org/regulatory-rapporteur-oct-2012


http://journals.lww.com/jinvestigativemed/Abstract/2012/10000/Translational_Research_and_the_Evolving_Landscape.5.aspx

http://www.expert-reviews.com/toc/erp/12/3


http://dij.sagepub.com/content/46/5/573


**This publication is for sale at our website  http://csdd.tufts.edu/reports
http://www.nature.com/clpt/journal/vaop/ncurrent/full/clpt201287a.html


http://www.pharmafocusasia.com/research_development/


Getz KA. Outsourcing landscape. *Applied Clinical Trials.* 2012; 21(5)(suppl):S22-S26 [RS 3217]
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Feature+Article/Outsourcing-Landscape/ArticleStandard/Article/detail/772232


http://www.landesbioscience.com/journals/mabs/ReichertMABS4-3.pdf


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=763940&sk=&&date=&&pageID=1

http://jme.bmj.com/content/early/2012/03/01/medethics-2011-100411/reply#medethics_el_3952

http://dx.doi.org/10.1016/j.nbt.2012.02.001

http://www.landesbioscience.com/journals/mabs/article/18812/


Getz KA. Profound changes in the outsourcing landscape. Pharmaceutical Executive. Published February 29, 2012. [web document] [RS 3206]

**This publication is for sale at our website http://csdd.tufts.edu/reports
http://dx.doi.org/10.1038/nrd3677

http://dx.doi.org/10.1038/clpt.2011.338


Kaitin KI. Creating innovation nodes to meet unmet medical needs. Pharmaceutical Technology. 2011;35(12):27 [RS 3132]

Getz KA. Transforming legacy R&D through open innovation. ACRP Monitor. 2011;25(7):17-21 [RS 3131b]


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Kaitin KI, editor. Nearly 60% of all protocols require amendments; one-third are avoidable. Tufts Center for the Study of Drug Development Impact Report. 2011 Sep/Oct;13(5)** [RS 3128]


**This publication is for sale at our website http://csdd.tufts.edu/reports**


Kaitin KI. 21st Century innovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. *Pharmaceutical Technology*. 2011;35(6):32 [RS 3119]  


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Reichert JM. The amazing, multipurpose antibody. *mAbs.* 2011;3(3):221-222. doi:org/10.4161/mabs.3.3.15625 [RS 3116b]
http://www.landesbioscience.com/journals/mabs/article/15625/

http://www.futuremedicine.com/action/doSearch?target=article&journal=pme&searchText=cohen+joshua&filter=single&x=25&y=10


http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=719542&sk=9270beba3a37ef7e37f3fa5477eea1cf9%22


Kaitin KI, editor. New or modified indications for existing drugs have steadily increased in the U.S. *Tufts Center for the Study of Drug Development Impact Report.* 2011 Mar/Apr;13(2)** [RS 3111]

http://www.landesbioscience.com/journals/mabs/article/14788/

http://dij.sagepub.com/content/45/2/119.full.pdf+html

Getz KA. Low hanging fruit in the fight against inefficiency. *Applied Clinical Trials.* 2011;20(3):30-32 [RS 3109]
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Low-Hanging-Fruit-in-the-Fight-Against-Inefficiency/ArticleStandard/Article/detail/711311?contextCategoryId=37194

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://www.nature.com/clpt/journal/v89/n2/full/clpt2010286a.html


Getz KA. The ultimate act of appreciation of study volunteers. *Focus*. 2011;3:8-12 [RS 3106b]

http://www.landesbioscience.com/journals/mabs/article/13895/


http://www.nature.com/nrd/journal/v10/n1/full/nrd3296.html


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=703033&sk=&date=&pageID=2


Reichert JM. Metrics for antibody therapeutics development. *mAbs.* 2010;2(6):695-700 [RS 3029]
http://www.landesbioscience.com/journals/mabs/article/13603/

Milne CP, Kaitin KI. Impact of the new US health-care-reform legislation on the pharmaceutical industry; who are the real winners? *Clinical Pharmacology & Therapeutics*. 2010;88(5):589-92 [RS 3028]
http://www.nature.com/clpt/journal/v88/n5/full/clpt2010167a.html

http://www.nature.com/nbt/journal/v28/n11/full/nbt1110-1160.html

Getz KA. Hurry up and wait, pharma puts the brakes on strategic outsourcing partnering. *Inside Outsourcing*. 2010 Nov;10-16 [RS 3026b]
http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12

http://license.icopyright.net/rights/offer.act?inprocess=t&sid=13&tag=3.7442%3Ficx_id%3D693552


Getz KA. Providing results to volunteers. *Applied Clinical Trials*. 2010;19(10):52-59 [RS 3023b]

http://license.icopyright.net/rights/tag.act?tag=3.7442%3Ficx_id=686210


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Getz KA. Engaging pharmacists in research education. *Applied Clinical Trials*. 2010;19(7):30-32


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0010610


RS 3012 Getz K. FIPNet: Pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials*. 2009;Suppl:10-12,14,16

Author manuscript; available in PMC 2011 August 4. PMCID: PMC3150117  
http://www.pharmoutsourcing.com/Featured-Articles/37572-The-Landscape-for-Pharmaceutical-Innovation-Di

RS 3010b Getz KA. Conversations with study volunteers. *Applied Clinical Trials*. 2010;19(5):32-34  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/Conversations-With-Study-Volunteers/ArticleStandard/Article/detail/668513


RS 3009 Getz KA. Sizing up the clinical research market. *Applied Clinical Trials*. 2010;19(3):32-34  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=660749

RS 3008 Getz KA. With clinical data, less is more. *Applied Clinical Trials*. 2010;19(1):28-30  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/With-Clinical-Data-Less-is-More/ArticleStandard/Article/detail/652123

doi:10.1093/protein/gzq018  

RS 3007b Getz KA. Understanding clinical trials: Appreciating medical heroes. *Media Planet*. 2010 Apr  

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
RS 3007  

RS 3006b  

RS 3006  

RS 3005  

RS 3004b  

RS 3004  
[http://www.nature.com/clpt/journal/v87/n3/full/clpt2009293a.html](http://www.nature.com/clpt/journal/v87/n3/full/clpt2009293a.html)

RS 3003  
[http://www.nature.com/clpt/journal/v87/n3/full/clpt2009295a.html](http://www.nature.com/clpt/journal/v87/n3/full/clpt2009295a.html)

RS 3002c  

RS 3002b  
[https://www.landesbioscience.com/journals/mabs/article/10786/](https://www.landesbioscience.com/journals/mabs/article/10786/)

RS 3002  

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://www.landesbioscience.com/journals/mabs/article/10059/?nocache=1260067508


RS2921b  Getz KA. Into the aftermath of M&A. *Applied Clinical Trials.* 2009;18(9)


http://www.es.landesbioscience.com/journals/mabs/article/9675/

http://www.landesbioscience.com/journals/mabs/article/9031/


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://www.nxtbook.com/nxtbooks/dia/druginformationjournal0709/#/118

RS 2915 Cohen J. Market access in the wake of NICE: biopharma’s friend or foe? European Pharmaceutical Review. 2009;48:8-12


http://kelly-landes.org/journals/17/article/9076/


http://www.landesbioscience.com/journals/mabs/article/7645/


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.landesbioscience.com/journals/17/article/8590/


Getz KA. Is clinical research recession proof. Applied Clinical Trials. 2009;18(3):32-34


Kaitin KI, editor. 75% of U.S. health plans reimburse off-label uses of prescription drugs. Tufts Center for the Study of Drug Development Impact Report. 2009 Mar/Apr;11(2)**


**This publication is for sale at our website http://cddd.tufts.edu/reports**


RS2833b Getz KA. Should physicians enroll their own patients into clinical trials? *ACRP Monitor.* 2008 Dec;22(7):34-38

**This publication is for sale at our website http://csdd.tufts.edu/reports**
| RS 2833 | Kaitin KI. Offshoring cost effective clinical research. *Pharma Focus Asia*. 2008; (9):55-6  
[http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm](http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm) |
| RS 2831 | Milne C-P Bruss JB. The economics of pediatric formulation development for off-patent drugs. *Clinical Therapeutics*. 2008;30(11):2133-45 |

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2825b  Getz KA. Getting to the heart of public distrust. *Applied Clinical Trials*. 2008; 17(9):38-42


http://www.manhattan-institute.org/html/mpr_06.htm


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 2815  Getz KA. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update*. 2008;Apr;4:5-6


RS 2809  Getz KA. In search of efficiency between trial phases. *Applied Clinical Trials*. 2008;17(3):35-38  


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://journals.lww.com/americantherapeutics/Citation/2008/01000/Follow_On_Drugs_and_Indications__The_Importance_of.15.aspx


http://www.nature.com/clpt/journal/v83/n2/full/6100462a.html


Getz KA. In search of informed consent improvement. *Applied Clinical Trials*. 2007;16(11):42-45

http://www.actmagazine.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Informed-Consent-Improvement/ArticleStandard/Article/detail/468090

DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics*. 2007;82(5):488-90

http://www.nature.com/clpt/journal/v82/n5/full/6100393a.html

Cohen JP. CEA is not a price control (letter). *Health Affairs*. 2007;26(5):1505

http://content.healthaffairs.org/cgi/reprint/26/5/1505

**This publication is for sale at our website http://csdd.tufts.edu/reports**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2704  Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials.* 2007;16(2):32-34  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454

http://classic.the-scientist.com/2006/12/1/49/1/

RS 2624b  Cohen J  Cairns C  Paquette C  Faden L. Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy.* 2006;5(3):177-87


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Kaitin KI, editor. Number of vaccines entering clinical study rose only modestly since 1990s. Tufts Center for the Study of Drug Development Impact Report. 2006 Jul/Aug;8(4)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports


RS 2606  Getz KA. Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence. *Applied Clinical Trials*. 2006;15(4):42-44
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473


http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=282477

RS 2601  Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials*. 2006;15(1):38-40
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633

RS 2517  Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials.* 2005;14(9):34-36  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&&pageID=1

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272

RS 2515  Milne C-P Kaitin KI. Down the critical path: who should lead? *Applied Clinical Trials.* 2005;14(8):56  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279


RS 2513  Sugarman J Getz K Speckman JL Byrne MM Gerson J Emanuel EJ  

RS 2512  DiMasi JA Hansen RW Grabowski HG. Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder. *Journal of Health Economics* 2005 Sep;24(5):1049-53


RS 2510  Kaitin KI, editor. Longer clinical times are extending time to market for new drugs in U.S. *Tufts Center for the Study of Drug Development Impact Report.* 2005 Nov/Dec;7(6)**

RS 2509  Reichert JM Rosensweig CJ Faden LB Dewitz MC. Monoclonal antibody successess in the clinic. *Nature Biotechnology* 2005;23(9):1073-8  


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=149965


http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=166546


RS 2423  Milne C-P. Harbingers, or harvesters of change? *European Pharmaceutical Review Supplement (Outsourcing).* 2004 Winter:12-17


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  [http://csd.tufts.edu/reports](http://csd.tufts.edu/reports)**


RS 2312  Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report.* 2003 Sep/Oct;5(5)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2301  Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report.* 2003 Jan/Feb;5(1)**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2218  Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. Tufts Center for the Study of Drug Development Impact Report. 2002 Nov/Dec;4(6)**

RS 2217  Franco RJ  Kaitin KI. Beyond the blockbuster: big pharma must rethink product development, striving for the speed and flexibility of mid-size players. Pharmaceutical Executive. 2002;22(11):74-80  
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=36729


http://www.nature.com/nbt/journal/v20/n7/abs/nbt0702-659.html

RS 2211  Cohen J  Chee J. Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. Disease Management & Health Outcomes. 2002;10(4):221-7


**This publication is for sale at our website  
http://csdd.tufts.edu/reports


Reichert JM Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics.* 2002:4(2):110-8


Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) *La Vanguardia* (Barcelona). 2001 18 Mar*


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS2118b Cohen J. The interaction of state, multistate, and federal initiatives to control prescription drug costs in the United States. Decision Resources. 2001 Sep;12:1-12


**This publication is for sale at our website  http://csdd.tufts.edu/reports


RS 2102 Kaitin KI, editor. FDA’s fast track program results in 62% approval rate after first 3 years. Tufts Center for the Study of Drug Development Impact Report. 2001 Jan/Feb;3(1)**


**This publication is for sale at our website http://csdd.tufts.edu/reports**
Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report.* 2000 Dec;2(9)


Kaitin KI. Don’t turn back the clock on drug regulatory reform. *Tufts Center for the Study of Drug Development Impact Editorial.* 2000 Sep;2(7)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2008  Drug firms embrace pediatric study program during first 2 years of FDAMA.  *Tufts Center for the Study of Drug Development Impact Report.*  2000 Apr;2(3)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9912  Planning, independence, feedback keep global R&D projects on track.  Tufts Center for the Study of Drug Development Impact Report. 1999 Sep;1(3)

RS 9911  Clinical development times for new drugs drop 18%, reversing 12-yr trend.  Tufts Center for the Study of Drug Development Impact Report. 1999 Jul;1(2)


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 9810  Lasagna L.  Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine. *Journal of Clinical Pharmacology*. 1998;38:570-1, 575-6


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


RS 9715  Kaitin KI.  FDA reform: setting the stage for efforts to reform the agency. *Drug Information Journal.* 1997;31(1):27-33

RS 9714  Lasagna L  DiMasi JA.  Let’s speed up the approval of new indications for old drugs. *Medical Marketing & Media* 1996;31(12):88-9

  [http://www.nature.com/clpt/journal/v60/n6/abs/clpt1996527a.html](http://www.nature.com/clpt/journal/v60/n6/abs/clpt1996527a.html)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 9625  DiMasi JA. *Written testimony*. House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996


RS 9623  Kaitin KI. *Statement*. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives, The Need for FDA Reform, February 27, 1996. 104th Congress 2d Session:81-7, 100-1


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)

Shulman SR, Seibring M, Manocchia M. *Letter to Hon. Judd Gregg, U.S. Senate.* Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

PS 9596  Brown JS DiMasi JA Gosse ME Manocchia M Kaitin KI Shulman SR. *Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider.* For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995


RS 9594  Bloom BR. The United States needs a national vaccine authority. *Science* 1994 Sep 2;265(5177):1378-80


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Inman WHW. Drug Safety Research Unit, University of Southampton. PEM News. 1993 Nov;(8).


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 9274  Shulman SR  Raiford DS. Promotional elements in educational programs: FDA attempts to wipe the slate clean.  P&T. 1992;17:661-73*


RS 9271  Kaitin KI  Walsh HL. Are initiatives to speed the new drug approval process working?  Drug Information Journal. 1992;26:341-9


RS 9266  Scoville B. Shifting the burden: restructuring the drug review process.  Journal of Clinical Pharmacology and Therapeutics. 1991;49(3):229-33


RS 9264  Kaitin KI. Case studies of expedited review: AZT and L-Dopa.  Law, Medicine & Health Care. 1991;19(3-4):242-6


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Shulman SR. La legislazione sulla responsabilità di produzione. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:27-8

Lasagna L. Le attività del Centro per lo Studio dello Sviluppo dei Farmaci. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26

Inman WHW. Drug Safety Research Unit, University of Southhampton, *PEM News*. 1988 Sep(5)


Shulman SR Raiford DS. FDA regulations provide broader access to unapproved drugs. *Journal of Clinical Pharmacology*. 1990;30:585-7


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8941  Kaitin KI. Reply to “understanding comparisons of drug introductions between the United States and the United Kingdom”. *Clinical Pharmacology & Therapeutics.* 1989 Aug;46(2);146-8


RS 8934  Grabowski HG. Medicaid patients' access to new drugs. *Health Affairs* 1989;7:102-14


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News.* 1988 Sep;(5)


Shulman SR. Drug refusal policy must include legal definition of competence. *Hospital Formulary.* 1988 Jan;23:79

DiMasi JA. The notion of "acceptable risk": comment. *Journal of Clinical Epidemiology.* 1988;41(9):939-41


Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? *Cancer Treatment Reports.* 1987;71:795-806


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8710  Inman WHW.  Drug Safety Research Unit, University of Southampton,  *PEM News.* 1987 Mar;(4)


RS 8705  Kaitin KI.  Impact of generic drugs on the pharmaceutical marketplace.  *Private Practice.* 1986 Sep;18:18-20 (Originally appeared as "Generic firms shun research, share rewards.")


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8608 Lasagna L. The economics of generic prescribing: winners and losers. JAMA. 1986 Nov 14;256(18):2566


RS 8601 Sharlin HI. EBD: a case study in communicating risk. Risk Analysis 1986;6(1):61-8

RS 8600 Berry CL. Unprovable verities. Human Toxicology. 1985;5(3):159-60

RS 8699 Weintraub M Northington F. Drugs that wouldn't die. Journal of the American Medical Association. 1986 May 2;255(17):2327-8


RS 8696 Inman WHW. Drug Surveillance Research Unit, University of Southampton. PEM News. 1985 Dec;(3)

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kitch E. Vaccines and product liability: a case of contagious litigation. Regulation. 1985 May/Jun


Walker SR Schultz E Schuppan D Gelzer J. A comparative retrospective analysis of data for short- and long-term animal toxicity studies on 40 pharmaceutical compounds. Archives of Toxicology. 1984;7:485-7


Mattison N. Sources of change affecting the U.S. pharmaceutical industry in the 1980s. Pharmaceutical Medicine. 1985;1:13-6*


**This publication is for sale at our website http://csdd.tufts.edu/reports**


RS 8478  Lasagna L. *Impediments to Vaccine Research, Medicine in the Public Interest Conference, Jan 9-10, 1984*. Boston: MIPI;1984

RS 8477  Inman WHW. Drug Surveillance Research Unit, University of Southampton, *PEM News*. 1984 Aug;(2)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 8474  Weintraub M.  P&T committees and drug regulation in Norway: lessons to be learned. *Hospital Formulary.* 1984;19:347


RS 8468  Hutt PB.  The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. *Health Affairs.* 1982;1(2):5-24


**This publication is for sale at our website**  http://csdd.tufts.edu/reports


RS 8367  Superior Court of New Jersey, Appellate Division. Carol Ann Feldman, an infant, by her parent and guardian *ad litem* Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

RS 8366  Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News.* 1983 Aug;(1)

RS 8365  Covington TR. Toward a rational approach to the issue of prescribing authority for pharmacists. *Drug Intelligence and Clinical Pharmacy.* 1983;17(9):660-6


**This publication is for sale at our website  [http://csdd.tufts.edu/reports]**
RS 8359  Diggle GE  Griffin JP.  Licensing times in granting marketing authorizations for medicines--a comparison between the U.K. and U.S.A.  *Pharmacy International.*  1982;3(7):230-6


RS 8358b  Zbinden G  Flury-Roversi M.  Significance of the LD 50 test for the toxicological evaluation of chemical substances.  *Archives of Toxicology.*  1981 Apr;47(2):77-99


RS 8357b  Mahler H.  Essential drugs for all.  *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982:64-70*

RS 8357  Lall S.  The pharmaceutical industry in India: the economic costs of regulation.  *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982:51-7*


RS 8262  Wardell WM.  Is pharmaceutical innovation declining?  *Pharmaceutical Technology.*  1982 Sep


RS 8260  Wardell WM  Mattison N.  The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis.  In:  *WMA Follow-up Committee on Development and Allocation of Medical Care Resources.*  Tokyo: Japan Medical Association;1982;84-98*

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 8253b | Schweiker RS. Remarks by the Honorable Richard S. Schweiker to the National Pharmaceutical Council Symposium. June 23, 1982 |
| RS 8252 | Shubin S. The MAC program and advisors to the government. *Hospital Formulary* 1981 Aug;16(8):869-79 |
| RS 8250 | Wardell WM. A statement on pharmaceutical patent life and innovation. Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982 |

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


RS 8153  Wardell WM, Velo GP, editors. Drug development, regulatory assessment, and postmarketing surveillance. NATO Advanced Institutes Series, 39 (Series A: Life Sciences) New York: Plenum; 1981*


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8059  Hansen RW. Effects of incremental costs on pharmaceutical innovation. (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

RS 8058  Hansen RW. The cost of regulation in the pharmaceutical industry: economic implications of three recent studies. (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 8057 | Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources*. Tokyo: Japan Medical Association, 1980:139-50* |
| RS 8056 | Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). *Private Practice*. 1980 Oct:24-31* |
| RS 8051 | Lasagna L. Pharmacology's labs have moved faster than the regulators. *Medical Tribune*. 1980 May 7;21:17 |
| RS 8046 | Hansen RW. *Pharmaceutical development costs by therapeutic categories*. (Working Paper Series No. GPB-80-6) Rochester, NY: Graduate School of Management, University of Rochester; Mar 1980* |

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8039  Letters to the editor. in re: the drug lag.  Regulation. 1980 Mar/Apr;4(2):59-60


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

Merrill RA. Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials. Rochester, NY: Center for the Study of Drug Development; Apr 1980


**This publication is for sale at our website http://csdd.tufts.edu/reports**


RS 7939  Lasagna L. Toxicological barriers to providing better drugs. Archives of Toxicology. 1979;43(1):27-33

RS 7938  Lasagna L. Prescription drugs: the investment with the biggest dividends. Private Practice. 1979;11(5):42-3


**This publication is for sale at our website http://csdd.tufts.edu/reports**
RS 7930  Lasagna L. The uncertain future of drug development. Drug Intelligence and Clinical Pharmacy. 1979;13(4):192-4


RS 7927  Wardell WM. Rx: more regulation or better therapies. Regulation. 1979 Sep/Oct;3(5):25-33

RS 7926b  Lasagna L. The diseases and drug needs of the Third World. Journal of Chronic Diseases. 1979;32(6):413-4


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 7823  Wardell WM. A close inspection of the 'calm look': rhetorical ambyopia and selective amnesia at the FDA. *Journal of the American Medical Association.* 1978;239(19):2004-11


PS 7816  Landau RL. *What you should know about estrogens, or the perils of Pauline.* Rochester, NY: Center for the Study of Drug Development; Jun 1978

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)